-The Telegraph New Delhi: Health activists campaigning for affordable treatment on Wednesday urged the Narendra Modi government to resist "pressure" from foreign medical device makers and expand price caps to new classes of medical devices. The All India Drug Action Network (AIDAN), a consortium of non-government activists' groups, said it was concerned that a body of foreign medical device manufacturers had petitioned the US government seeking suspension or withdrawal of certain trade...

-The Times of India In a first for a medical device, the public interest provision in the Drug Price Control Order (DPCO) 2013 was used by the National Pharmaceutical Pricing Authority to cap the price of knee implants. The NPPA cited "exorbitant prices being charged from patients in a non-regulated market" and "a failed market system where asymmetry of information between patient and the doctor has resulted into unethical practices and...

-The Hindu Business Line Industry likely to meet officials today New Delhi: Patients with debilitating knee problems, requiring joint replacement surgeries, would soon regain spring in their steps. The National Pharmaceutical Pricing Authority (NPPA), which capped the prices of coronary stents in February, may cap the prices of knee implants soon. According to a source in the know of the developments, the price of knee implants is likely to be capped with just...

-PTI The government has formed a committee in its bid to make drugs more affordable in the country, Parliament was informed on Tuesday. “Government has constituted a committee of joint secretaries for ensuring enhanced affordability, availability and accessibility of drugs for the citizens,” Minister of State for Chemicals and Fertilisers Mansukh L. Mandaviya said in a written reply to Lok Sabha. Elaborating on the terms of reference of the committee, the minister said...

-The Indian Express Responding to specific queries on the issue, Bhupendra Singh, NPPA chairman, told The Indian Express that “examination of hospital records is in process”. AFTER the National Pharmaceutical Pricing Authority (NPPA) in February ordered a cap on the prices of coronary stents and directed hospitals to issue separate bills specifying their cost, the drug pricing watchdog has started receiving consumer complaints against hospitals which are allegedly hiking the prices...